	US 12,391,743 B2
	TGF-β-receptor ectodomain fusion molecules and uses thereof
John C. Zwaagstra, Laval (CA); Traian Sulea, Kirkland (CA); Maria L. Jaramillo, Beaconsfield (CA); Maureen D. O'Connor, Beaconsfield (CA); and Anne E. G. Lenferink, Lorraine (CA)
Assigned to National Research Council of Canada, Ottawa (CA)
Filed by National Research Council of Canada, Ottawa (CA)
Filed on Nov. 10, 2021, as Appl. No. 17/523,602.
Application 17/523,602 is a continuation of application No. 15/755,595, abandoned, previously published as PCT/IB2016/055204, filed on Aug. 31, 2016.
Claims priority of provisional application 62/212,058, filed on Aug. 31, 2015.
Prior Publication US 2022/0169702 A1, Jun. 2, 2022
Int. Cl. C07K 14/71 (2006.01); A61P 35/00 (2006.01); C07K 16/22 (2006.01); A61K 39/00 (2006.01)

CPC C07K 14/71 (2013.01) [A61P 35/00 (2018.01); C07K 16/22 (2013.01); A61K 2039/505 (2013.01); C07K 2317/94 (2013.01); C07K 2319/30 (2013.01)]

14 Claims

1. A polypeptide construct comprising:

a first portion comprising the second constant domain (CH2) and/or third constant domain (CH3) of an antibody heavy chain, and

a second portion comprising at least two TGF-β superfamily receptor ectodomains (TβSR-ED) linked in tandem,

wherein the N-terminus of the second portion is linked to the C-terminus of the first portion,

wherein the at least two TβSR-EDs are TGF-β receptor II ectodomains (TβR-II-EDs), and

wherein the polypeptide construct has neutralization activity against TGF-β2.